CN108299473B - Complex of copper and benzimidazole compound containing pyridine and application thereof - Google Patents

Complex of copper and benzimidazole compound containing pyridine and application thereof Download PDF

Info

Publication number
CN108299473B
CN108299473B CN201810184361.4A CN201810184361A CN108299473B CN 108299473 B CN108299473 B CN 108299473B CN 201810184361 A CN201810184361 A CN 201810184361A CN 108299473 B CN108299473 B CN 108299473B
Authority
CN
China
Prior art keywords
alkoxy
compound
pharmaceutically acceptable
bis
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810184361.4A
Other languages
Chinese (zh)
Other versions
CN108299473A (en
Inventor
胡春
张雅馨
高迪
常楚晴
陈固洲
王婧
黎晓丹
王菲
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenyang Pharmaceutical University
Original Assignee
Shenyang Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenyang Pharmaceutical University filed Critical Shenyang Pharmaceutical University
Priority to CN201810184361.4A priority Critical patent/CN108299473B/en
Publication of CN108299473A publication Critical patent/CN108299473A/en
Application granted granted Critical
Publication of CN108299473B publication Critical patent/CN108299473B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F1/00—Compounds containing elements of Groups 1 or 11 of the Periodic Table
    • C07F1/005—Compounds containing elements of Groups 1 or 11 of the Periodic Table without C-Metal linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention belongs to the technical field of medicines, and relates to a novel copper complex, namely a complex of copper and a pyridine-containing benzimidazole compound, a composition containing the complexes, and application of the complexes in preparation of antitumor drugs. The structure of the compound of the invention is shown as the following formula (I): wherein R is selected from H, C1-C6 alkoxy, halogenated C1-C6 alkoxy, hydroxyl, amino, nitro and cyano; r1Selected from H, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, hydroxyl, amino, nitro and cyano; r2Selected from H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy; the substituent is C1-C6 alkoxy, halogenated C1-C6 alkoxy; r3Selected from H, C1-C6 alkyl, C1-C6 alkoxy. The complex and the composition containing the complex can be used for preparing anti-tumor medicines.

Description

Complex of copper and benzimidazole compound containing pyridine and application thereof
Technical Field
The invention relates to a novel copper complex, namely a complex of copper and a benzimidazole compound containing pyridine, a composition containing the complexes and application of the complexes in preparing an anti-tumor medicament.
Background
Malignant tumors are one of the most serious diseases recognized in the world as being harmful to human health, and the harm is second to cardiovascular diseases. Therefore, the research of tumor treatment is enhanced, the effect of the existing various treatment means is improved, the cancer death rate is reduced, the recurrence rate is reduced, the life quality of cancer patients is improved, and the method has important social benefit and huge economic benefit. In tumor therapy, chemotherapy is one of the important methods for current tumor therapy. Among the chemotherapeutic drugs, platinum group compounds are a class of drugs with strong antitumor effect and wide antitumor spectrum. Since cisplatin (cispinin) was found to have antitumor activity by Rosenberg et al in 1967, it has been widely used as a highly potent antitumor agent for the treatment of various cancers such as testicular cancer, ovarian cancer, cervical cancer, bladder cancer, lung cancer, and head and neck cancer, etc. (Wong E, Giandomenic CM. Current status of planar-based anticancer or drugs. chem Rev,1999,99(9): 2451-2466.). Subsequently, a series of platinum compounds such as carboplatin (carboplatin), nedaplatin (nedaplatin), oxaliplatin (oxaliplatin), loplatin (lobaplatin), and cycloplatin (cycloplatin) have been successfully used clinically as antitumor metal drugs (Abu-SurrahAS, Ketton M. platinum group anticancer chemistry: design and development of new anticancer drugs to cancer. Current Med Chem,2006,13(11): 1337-57), but development of novel transition metal complex antitumor drugs is also drawing attention due to problems such as toxicity and drug resistance of platinum group compounds.
Meanwhile, copper, which is an essential trace element for biology, exists in the active sites of metalloproteins and metalloenzymes in the living body, and participates in maintaining normal physiological functions in the living body, has important effects on the development of hematopoietic system and central nervous system, the formation of bone and connective tissue, the deposition of skin pigment, etc., and has unique catalytic effect in the oxidation-reduction system in living organisms, plays a key role in the aging and cancer and DNA damage caused by endogenous oxidants associated with the cancer (Wang Feili, everbright, Anlihu, etc. research progress of non-platinum metal anti-cancer compounds, chemical research and application, 2003,15(5): 612. 616.), and the toxicity of copper is less than that of non-essential trace elements such as platinum, therefore, the copper metal complex is expected to maintain the antitumor activity of the platinum group compound and has the characteristic of low toxicity.
On the basis of synthesizing some benzimidazole compounds containing pyridine groups, the invention takes the benzimidazole compounds as ligands to synthesize a series of complexes of copper and benzimidazole compounds containing pyridine, and the complexes have obvious antitumor activity and are expected to become novel candidate drugs for antitumor treatment.
Disclosure of Invention
The invention aims to provide a compound shown as a formula I, a prodrug, a pharmaceutically active metabolite and a pharmaceutically acceptable salt thereof, and provides application of the compound in preparation of antitumor drugs.
The structure of the compound of the invention is shown as the following formula (I):
Figure BDA0001589818560000021
wherein,
r is selected from H, C1-C6 alkoxy, halogenated C1-C6 alkoxy, hydroxyl, amino, nitro and cyano;
R1selected from H, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy, hydroxyl, amino, nitro and cyano;
R2selected from H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy; the substituent is C1-C6 alkoxy, halogenated C1-C6 alkoxy;
R3selected from H, C1-C6 alkyl, C1-C6 alkoxy.
Preferably, the first and second electrodes are formed of a metal,
r is selected from H, C1-C4 alkoxy, halogenated C1-C4 alkoxy;
R1selected from H, C1-C4 alkyl, C1-C4 alkoxy;
R2selected from H, C1-C4 alkyl, substituted or unsubstituted C1-C4 alkoxy, wherein the substituent is C1-C4 alkoxy, and halogenated C1-C4 alkoxy;
R3selected from H, C1-C4 alkyl, C1-C4 alkoxy.
Further, the air conditioner is provided with a fan,
r is selected from H, methoxy, difluoromethoxy;
R1selected from H, methyl, methoxy;
R2selected from H, methyl, methoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2,2, 2-trifluoroethoxy;
R3selected from H, methyl and methoxy.
The term "pharmaceutically acceptable salt" refers to conventional acid addition salts or base addition salts which retain the biological effectiveness and properties of the compounds of formula I and which are formed with suitable non-toxic organic or inorganic acids or organic or inorganic bases, the acid addition salts include hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, sulfate, perchlorate, thiocyanate, bisulfate, persulfate, borate, formate, acetate, propionate, valerate, pivalate, hexanoate, heptanoate, octanoate, isooctanoate, undecanoate, laurate, palmitate, stearate, oleate, cycloproponate, oxalate, malonate, succinate, maleate, fumarate, adipate, azelate, acrylate, strawberry, crotonate, tiglate, itaconate, sorbate, cinnamate, glycolate, malate, tartrate, citrate, tartrate, mandelate, prolinate, ascorbyl, gluconate, glucarate, mannitol, maleate, tartrate, phenazinate, phenalenoate, cinnamate.
"pharmaceutically acceptable" such as pharmaceutically acceptable carriers, excipients, prodrugs, etc., means pharmacologically acceptable and substantially non-toxic to a patient to whom a particular compound is administered.
"pharmaceutically active metabolite" refers to a pharmaceutically acceptable and effective metabolite of a compound of formula I.
The invention also relates to pharmaceutical compositions comprising formula I or a stereoisomer thereof or a pharmaceutically acceptable acid addition salt thereof, in combination with a pharmaceutically acceptable carrier.
Certain crystalline forms of the compounds may exist as polymorphs and as such are included in the present invention. In addition, some compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also within the scope of the present invention.
The present invention includes within its scope prodrugs of the compounds of the present invention. In general, such prodrugs will be functional derivatives of the present compounds that are readily converted in vivo to the desired compound. Thus, in the methods of treatment of the present invention, the term "administering" shall encompass the treatment of the various described conditions with a compound specifically disclosed, or with a compound that is not specifically disclosed but which converts to the specified compound in vivo in the patient upon administration.
The following reaction scheme outlines the preparation steps for preparing the compounds of the present invention.
Figure BDA0001589818560000041
Reaction scheme
The invention also relates to a complex of copper and benzimidazole compound containing pyridine as an antitumor drug for treating tumors.
Methods of treatment and dosages used
The various diseases and conditions to be treated described herein are well known and clear to those skilled in the art. It is also understood that one skilled in the art can treat a patient currently afflicted with a disease or condition with a therapeutically effective amount of the compound or affect the disease or condition by prophylactically treating a patient afflicted with a disease or condition.
The term "patient" as used herein refers to a warm-blooded animal, such as a mammal, having a tumor. It is understood that guinea pigs, dogs, cats, rats, mouse horses, cattle, sheep, and humans are examples of animals within the meaning of the term.
The term "therapeutically effective amount" as used herein refers to an amount effective for the control of tumor-associated diseases and conditions. The term "controlling" is intended to refer to all processes by which the progression of the diseases and conditions described herein can be slowed, interrupted, arrested or halted, and not necessarily the complete elimination of all of the symptoms of the disease and condition.
A therapeutically effective amount can be readily determined by the attending diagnostician as one skilled in the art using routine techniques and observing results obtained under analogous circumstances. In determining a therapeutically effective amount of a dosage, the attending diagnostician considers a number of factors, including but not limited to: the species of mammal; its size, age and general health; the specific diseases involved; the degree or complexity or severity of the disease; the response of the individual patient; the particular compound administered; the mode of administration; bioavailability characteristics of the administered formulation; a selected dosing regimen; concomitant medication use and other related conditions.
Therapeutically effective amounts of the compounds are expected to vary from about 0.001 milligrams per kilogram of body weight per day (mg/kg/day) to about 100 mg/kg/day. Preferred amounts can be determined by one skilled in the art.
In effectively treating patients suffering from the diseases and conditions described above, such compounds may be administered in any form or manner that makes the compound bioavailable in therapeutically effective amounts, including oral, inhaled, and parenteral routes. For example, the compounds can be administered orally, by inhalation as an aerosol or dry powder, by subcutaneous injection, intramuscular injection, intravenous injection, transdermal administration, intranasal administration, rectal administration, topical administration, and the like. Oral or inhalation administration is generally preferred for the treatment of respiratory diseases such as asthma. One skilled in the art of formulating formulations can readily select the appropriate form and mode of administration depending on the particular characteristics of the compound selected, the condition of the disease or condition to be treated, the stage of the disease or condition, and other relevant circumstances.
The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or excipients in the form of pharmaceutical compositions, the proportions and properties of which are determined by the solubility and chemical properties of the compound selected, the route of administration selected, and standard pharmaceutical practice. The compounds of the present invention, while effective per se, may be formulated and administered in the form of their pharmaceutically acceptable salts, such as acid or base addition salts, for the purposes of stability, ease of crystallization, improved solubility, and the like.
The present invention provides pharmaceutical compositions comprising a therapeutically effective amount of a compound admixed or otherwise associated with one or more pharmaceutically acceptable carriers or excipients.
The pharmaceutical compositions are prepared according to methods well known in the pharmaceutical art. The carrier or excipient which may serve as a vehicle or medium for the active ingredient may be a solid, semi-solid, or liquid material. Suitable carriers or excipients are well known in the art. The pharmaceutical compositions may be adapted for oral, inhalation, parenteral or topical use and may be administered to the patient in the form of tablets, capsules, aerosols, inhalants, suppositories, solutions, suspensions and the like.
The compounds of the present invention may be administered orally, for example, with an inert diluent or with an edible carrier, which may be enclosed in capsules or compressed into tablets. For oral therapeutic administration, the compounds may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gums and the like. These formulations should contain at least 4% of the compound of the invention, i.e. the active ingredient, but may vary depending on the particular form, conveniently between 4% and about 70% by weight of the unit. The amount of the compound present in the composition should be such that a suitable dosage is obtained. Preferred compositions and formulations of the present invention may be determined by one skilled in the art.
The tablets, pills, capsules, lozenges and the like may further contain one or more of the following adjuvants: binders such as microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch or lactose, disintegrants such as alginic acid, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil. Other dosage unit forms may contain other, different materials that modify the physical form of the dosage unit, for example as a coating. Syrups, in addition to containing the compound, may contain sucrose as a sweetening agent and certain preservatives, dyes and colorings and flavors. The materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
For parenteral administration, the compounds of the invention may be added to a solution or suspension. These formulations should contain at least 0.1% of the compound of the invention, but may vary between 0.1 and about 50% by weight of the formulation. The amount of compound present in such compositions should be such that a suitable dosage is obtained. Preferred compositions and vitex negundo can be determined by a person skilled in the art.
The compounds of the invention may also be administered by inhalation, for example as an aerosol or dry powder. May be released by a liquefied or compressed gas or by a suitable pumping system which dispenses the compounds of the invention or their formulations. Formulations for administration by inhalation of the compounds may be delivered in monophasic, biphasic or triphasic systems. For aerosol administration of the compounds, a number of systems are available. Dry powder formulations are prepared by granulating or milling the compound to the appropriate particle size or by mixing the granulated or milled compound with a suitable carrier, such as lactose or the like. Delivery systems by inhalation include the necessary containers, active agents, valves, sub-containers, and the like. Preferred aerosol and dry powder formulations for administration by inhalation can be determined by one skilled in the art.
The compounds of the invention may also be administered topically, in which case the carrier will suitably contain a solution, ointment or gel base. The base may, for example, comprise one or more of the following substances: the concentration of the calcium-containing compound or pharmaceutically acceptable salt thereof in the topical formulation may be from about 0.1 to about 10% w/v (weight per unit volume).
The solution or suspension may also contain one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerin, propylene glycol or other synthetic solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as vitamin C or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for adjusting the osmotic pressure such as sodium chloride or glucose. The parenteral formulations may be presented in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
Drawings
FIG. 1 is a molecular structural diagram of complex G-12.
Detailed Description
Example 1: bis (. mu. -sulfate-O, O') bis {2- [ (3, 4-dimethoxy-2-pyridyl) methylthio-. kappa.N]-1H-benzimidazole-kappa N3Preparation of (II) (G-11) bis (copper (II) }
Figure BDA0001589818560000061
After 1.27g (7.97mmol) of copper sulfate pentahydrate was completely dissolved in 30mL of methanol, 2- [ (3, 4-dimethoxy-2-pyridyl) methylthio group was added dropwise thereto]Reacting 2.40g (7.97mmol) of (E) -1H-benzimidazole in 10mL of methanol at room temperature overnight, detecting by TLC, and after the reaction is completed, distilling off the methanol solution under reduced pressure to obtain a dark green solid, namely bis (mu-sulfate) bis {2- [ (3, 4-dimethoxy-2-pyridyl) methylthio ] methyl]3.67g (3.99mmol) of (E) -1H-benzimidazole-N, N' -ylidene } bipyramid (II). The yield was 100.0%. m.p:>250℃；HRMS:916.965191([M-H]-)；IR:3421.0,2923.9,1631.9,1602.3,1456.5,1339,1309.4,1276.0,1213.8,1106.5,1075,865.8,835.4。
example 2: bis (. mu. -sulfate-O, O') bis {2- [ (3, 4-dimethoxy-2-pyridyl) methylthio-. kappa.N]-1H-benzimidazole-kappa N3Preparation of copper (II) chloride solvate (G-12)
Figure BDA0001589818560000071
About 5mg of bis (. mu. -sulfate radical-O, O') bis {2- [ (3, 4-bis)Methoxy-2-pyridyl) methylthio-kappa N]-1H-benzimidazole-kappa N3And (4) dissolving the copper (II) completely in 5mL of methanol, adding acetone with different amounts, and preparing mixed solutions of methanol and acetone with different proportions. Wherein methanol is used as a good solvent and acetone is used as a poor solvent. The prepared mixed solution with different proportions is respectively placed in different small conical bottles with smooth inner walls, and after the bottle mouths are sealed by plastic packaging films, a plurality of small mouths are pricked, so that the solvent in the bottles can be volatilized slowly. And (5) placing the small conical flask in a quiet, light-proof and stable place for standing culture to obtain dark green crystals. Under high power microscope, selecting regular transparent single crystal particles, collecting the crystal diffraction data on Rigaku MSC X-ray crystal diffractometer, and resolving the crystal structure by SHELXL and SHELXS programs, wherein the unit cell parameters are shown in Table 1, and the crystal structure is shown in FIG. 1.
TABLE 1 Crystal Structure parameters of Complex G-12
Figure BDA0001589818560000072
Figure BDA0001589818560000081
Example 3: bis (. mu. -sulfate-O, O') bis { 5-difluoromethoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio-kappa.N]-1H-benzimidazole-kappa N3Preparation of (II) (G-13) bis (II)
Figure BDA0001589818560000082
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:1050.919246([M-H]-)；IR:3422.7,3105.5,2949.5,2725.3,2169.5,1631.0,1501.4,1460.7,1432.1,1356.3,1309.5,1283.1,1234.1.1303.4,1171.9,865.2,820.2。
example 4: bis (. mu. -sulfate-O, O') bis {2- { [ 3-methyl-4- (2,2, 2-trifluoromethoxy) -2-pyridyl]Methylthio-kappa N } -1H-benzimidazole-kappaN3Preparation of (II) (G-14) bis (II)
Figure BDA0001589818560000091
Referring to the preparation method of example 1, a pale purple flaky solid was obtained in a yield of 100.0%. m.p:>250℃；HRMS:1024.913695([M-H]-)；IR:3423.0,2923.6,2169.5,1696.7,1455.9,1401.7,1385.5,1338.1,1269.6,1166.1,1113.8,1038.3,960.8,865.1,834.5。
example 5: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (4-methoxy-3, 5-dimethyl-2-pyridyl) methylsulfanyl-. kappa.N]-1H-benzimidazole-kappa N3Preparation of (II) (G-15) bis (II)
Figure BDA0001589818560000092
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:976.994612([M-H]-)；IR:3424.8,2923.2,2169.5,1696.8,1456.7,1400.8,1385.1,1338.6,1272.7,1110.0,1053.5,1009.1,865.2,834.7。
example 6: bis (. mu. -sulfate-O, O') bis {2- [ (4-methoxy-3, 5-dimethyl-2-pyridyl) methylthio-kappa.N]-1H-benzimidazole-kappa N3Preparation of (II) (G-16) bis (II)
Figure BDA0001589818560000093
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:914.973830([M-H]-)；IR:3422.8,2923.6,2169.5,1696.6,1451.4,1385.3,1354.6,1274.1,1087.1,1039.1,995.4,865.4,835.0。
example 7: bis (. mu. -sulfate-O, O') bis { 5-difluoromethoxy-2- [ (4-methoxy-3, 5-dimethyl-2-pyridyl) methylsulfanyl-. kappa.N]-1H-benzimidazole-kappa N3Preparation of (II) (G-17) bis (II)
Figure BDA0001589818560000101
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:1046.958230([M-H]-)；IR:3422.4,2923.9,2169.5,1696.8,1457.0,1385.5,1338.9,1272.7,1124.6,1039.0,1007.6,865.3,834.7。
example 8: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- { [4- (2-methoxypropoxy) -3, 5-dimethyl-2-pyridinyl]methylthio-kappa-N } -1H-benzimidazole-kappa-N3Preparation of (II) (G-18) bis (II)
Figure BDA0001589818560000102
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:1063.050545([M-H]-)；IR:3422.1,2924.0,2169.5,1696.6,1458.3,1338.2,1273.7,1159.2,1096.0,1037.5,865.0,834.1。
example 9: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- { [ 2-methyl-4- (2,2, 2-trifluoromethyl) -2-pyridinyl]methylthio-kappa-N } -1H-benzimidazole-kappa-N3Preparation of (II) (G-19) bis
Figure BDA0001589818560000111
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:1082.939430([M-H]-)；IR:3424.2,2924.1,2169.5,1697.0,1457.2,1418.1,1262.5,1162.7,1036.9,963.8,863.2,834.3。
example 10: bis (. mu. -sulfate-O, O') bis { 5-methoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio-kappa.N]-1H-benzimidazole-kappa N3Preparation of (II) (G-20) bis (II)
Figure BDA0001589818560000112
Referring to the preparation method of example 1, dark green metallic lustrous powder was obtained with a yield of 100.0%. m.p:>250℃；HRMS:978.956264([M-H]-)；IR:3423.4,2924.9,2169.5,1697.0,1499.1,1458.3,1338.6,1308.7,1278.0,1115.5,1037.7,1003.3,865.0,835.0。
example 11: inhibitory Activity of test Compounds on proliferation of human liver cancer cell HepG2, human colon cancer cell SW480 and human normal liver cell HL7702
(1) Experimental Material
Cell lines: human liver cancer cell HepG2, human colon cancer cell SW480, and human normal cancer cell HL 7702; 10% newborn bovine serum (FBS); a 96-well plate; dulbecco's Modified Eagle Medium (DMEM).
Test compounds: L-01-L-16, C-01-C-16 total 32 compounds, dissolved in DMSO to 50mM and stored at-20 ℃ for later use, with the final concentration of DMSO in the culture solution being less than 0.1%.
MTT test: dissolved in PBS at 5mg/mL and stored at-20 ℃.
(2) Experimental methods
The antitumor activity of the test compounds was determined by the MTT method (Mosmann T. Rapid clinical laboratory for cellular growth and efficacy: application to promotion and cytoxicity assays. J Immunol methods.1983,65(1-2): 55-63).
HepG2 (liver cancer), SW480 (human colon cancer) and HL7702 (human normal liver cells) were cultured in cell Eagle medium (DMEM). The medium was Dulbecco's modified and contained 10% bovine serum (FBS), SW480 cell line and HepG2 cell line. The final concentration of each compound was 50uM and 25uM, 3 parallel wells per concentration. Cells were pooled when they proliferated to 80-90% followed by subculture for no more than 20 passages and then allowed to acclimate for 24h before further processing. These cells were plated in 96-well plates (8X 10)4/mL) and then in a solution containing 5% CO2Was incubated overnight in a humidified environment and temperature controlled at 37 ℃. After further incubation at 37 ℃ for 24h, the wells were individually filled with MTT (5mg/ml) solution, the plates were gently shaken, returned to the incubator and incubated for another 4h, and then the supernatant was aspirated off each wellAdding DMSO (100 μ L) into the wells, placing the wells on a shaker for shaking for 5-10 min to completely dissolve MTT, measuring the absorbance (OD value) at 490nm in each well with an enzyme-labeling photometer (TECAN SPECTRA, Wetzlar, Germany), and calculating the inhibition ratio according to the following formula (see Table 2).
Inhibition rate (1-drug OD/control OD) × 100%
Cisplatin is used as positive control drug, and IC of cisplatin for inhibiting proliferation of human liver cancer cell (HepG2) and human colon cancer cell (SW480)50Respectively 6.6 +/-1.0 mu mol/L and 15 +/-2.7 mu mol/L.
Experimental results show that the tested copper complexes have different inhibition effects on the proliferation of human liver cancer cells HepG2 and show a dose-effect relationship, only a few tested copper complexes have the inhibition effects on the proliferation of human colon cancer cells SW480, the inhibition effects of the tested copper complexes on the proliferation of human liver cancer cells HepG2 are stronger than the inhibition effects on the proliferation of human colon cancer cells SW480, and the tested copper complexes have almost no inhibition effects on the proliferation of human normal liver cells HL 7702.
TABLE 2 inhibition of various cell proliferations by test Compounds
Figure BDA0001589818560000121
Pharmaceutical composition
Example 13: tablet formulation
25-1000mg of active compound, 45mg of starch, 35mg of microcrystalline cellulose, 4mL of polyvinylpyrrolidone (as a 10% aqueous solution), 4.5mg of sodium carboxymethylcellulose, 0.5mg of magnesium stearate, and 1mg of talc.
Example 14: suspending agent formula
0.1-1000mg of active compound, 50mg of sodium carboxymethylcellulose, 1.25mg of syrup, 0.1mg of sodium benzoate, a proper amount of flavoring agent and a proper amount of coloring agent, and adding pure water to 5 mL.
Example 15: aerosol formulations
0.25mg of active compound, 25-75mL of ethanol and 70mg of propellant 22 (chlorodifluoromethane).
Example 16: suppository formula
250mg of active compound, 2000mL of saturated fatty acid glycerides.
Example 17: injectable formulation
50mg of active compound, 1000mL of isotonic saline solution.
Example 18: ointment formulation
0.025g of micronized active compound, 10g of liquid paraffin, and 100g of soft white wax.
Example 19: ointment formulation
0.025g of active compound, 5g of propylene glycol, 5g of sorbitan sesquioleate, 10g of liquid paraffin and 100g of soft white wax.
Example 20: oil-in-water cream formulation
0.025g of active compound, 5g of cetyl alcohol, 5g of glycerol monostearate, 10g of liquid paraffin, 10002 g g of Ce tomacriol, 0.1g of citric acid, 0.2g of sodium citrate, 35g of propylene glycol and water to 100 g.
Example 21: oil-in-water cream formulation
0.025g of micronized active compound, 15g of soft white wax, 5g of liquid paraffin, 5g of cetyl alcohol, 2g of Sorbimcarol stearate, 0.5g of sorbitan monostearate, 0.2g of sorbic acid, 0.1g of citric acid, 0.2g of sodium citrate, and water to 100 g.
Example 22: water-in-oil cream formulation
0.025g of active compound, 35g of soft white wax, 5g of liquid paraffin, 5g of sorbitan sesquioleate, 0.2g of sorbic acid, 0.1g of citric acid and 0.2g of sodium citrate, and water is added until the weight is 100 g.
Example 23: lotion formulation
0.25g of active compound, 0.5mL of isopropanol, 3mg of carboxyvinyl polymer, a suitable amount of NaOH and water to 1 g.
Example 24: suspension formulation for injection
0.05-10mg of active compound, 7mg of sodium carboxymethylcellulose, 7mg of NaCl, 0.5mg of polyoxyethylene (20) sorbitan monooleate, 8mg of benzyl alcohol, and sterile water to 1 mL.
Example 25: aerosol formulation for oral and nasal inhalation
0.1% w/w active compound, 0.7% w/w sorbitan trioleate, 24.8% w/w trichlorofluoromethane, 24.8% w/w dichlorotetrafluoroethane and 49.6% w/w dichlorodifluoromethane.
Example 26: atomized solution formulation
7mg of active compound, 5mg of propylene glycol, water to 10 g.
Example 27: powder formulations for inhalation
Gelatine capsules were filled with a mixture of the following ingredients, micronised active compound 0.1mg, lactose 20mg and the powder was inhaled with the aid of an inhalation device.
Example 28: powder formulations for inhalation
The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound per dose.
Example 29: powder formulations for inhalation
The spheronized powder was loaded into a multi-dose powder inhaler containing 0.1mg of micronized active compound and 1mg of micronized lactose per dose.
Example 30: capsule formulation
1.0 part of active compound, 321mg of small sugar spheres, 306.6 mg of Aquacoat ECD, 0.5mg of acetyl tributyl citrate, 800.1 mg of Tween-800, 100-5517.5 mg of Eudragit L, 1.8mg of triethyl citrate, 8.8mg of talcum powder and 0.lmg of defoamer MMS.
Example 31: capsule seedling formula
2.0mg of active compound, 305mg of small sugar spheres, Aquocoat ECD 305.0 mg, acetyl tributyl citrate 0.4mg, Tween-800.14 mg, Eudragit NE30D 12.6.6 mg, Eudragit S10012.6 mg, talc 0.l6 mg.
Example 32: enema formula
00.2mg of active compound, 25mg of sodium carboxymethylcellulose, 0.5mg of disodium ethylenediaminetetraacetate, 0.8mg of methylparaben, 0.2mg of propylparaben, 7mg of sodium chloride, 1.8mg of citric acid, 800.01 mg of tween-800, and 1mL of pure water.
Example 33: formulation containing liposome
A. Preparation of the instillation formulation
The synthesized dipalmitoyl lecithin (45mg), dimyristoyl lecithin (7mg), dipalmitoyl phosphatidylglycerol (1mg) and active compound (5mg) were mixed in a glass tube, and all components were dissolved in chloroform with N2Adding an aqueous solution (0.9% NaCl) to the lipids, forming liposomes at a temperature above the phase inversion temperature of the lipids, the resulting suspension containing liposomes ranging in size from very small vesicles to 2 μm.
B. Preparation of formulations for inhalation
Liposomes were prepared as in example A, with an aqueous solution containing 10% lactose at a 7:3 lactose to lipid ratio. The liposome suspension was frozen with dry ice and freeze-dried, and the dried product was micronized, and the Mass Mean Aerodynamic Diameter (MMAD) of the resulting particles was about 2 μm.
The foregoing is directed to preferred embodiments of the present invention, other and further embodiments of the invention may be devised without departing from the basic scope thereof, and the scope thereof is determined by the claims that follow. Any simple modification, equivalent change and modification of the above embodiments according to the technical essence of the present invention, without departing from the technical solution of the present invention, still belong to the protection scope of the technical solution of the present invention.

Claims (27)

1. A compound or pharmaceutically acceptable salt of formula (I):
Figure DEST_PATH_IMAGE001
wherein,
r is selected from H, C1-C6 alkoxy, halogenated C1-C6 alkoxy;
R1selected from H, C1-C6 alkyl, C1-C6 alkoxy, halogenated C1-C6 alkoxy;
R2selected from H, substituted or unsubstituted C1-C6 alkyl, C1-C6 alkoxy; the substituent is C1-C6 alkoxy, halogenated C1-C6 alkylAn oxy group;
R3selected from H, C1-C6 alkyl, C1-C6 alkoxy.
2. The compound or pharmaceutically acceptable salt of claim 1:
r is selected from H, C1-C4 alkoxy, halogenated C1-C4 alkoxy.
3. The compound or pharmaceutically acceptable salt of claim 1:
r is selected from H, methoxy and difluoromethoxy.
4. The compound or pharmaceutically acceptable salt of any one of claims 1-3:
R1selected from H, C1-C4 alkyl, C1-C4 alkoxy.
5. The compound or pharmaceutically acceptable salt of any one of claims 1-3:
R1selected from H, methyl and methoxy.
6. The compound or pharmaceutically acceptable salt of claim 4:
R1selected from H, methyl and methoxy.
7. The compound or pharmaceutically acceptable salt of any one of claims 1-3:
R2is selected from H, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, and the substituent is C1-C4 alkoxy and halogenated C1-C4 alkoxy.
8. The compound or pharmaceutically acceptable salt of claim 4:
R2is selected from H, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, and the substituent is C1-C4 alkoxy and halogenated C1-C4 alkoxy.
9. The compound or pharmaceutically acceptable salt of claim 5:
R2is selected from H, substituted or unsubstituted C1-C4 alkyl, C1-C4 alkoxy, and the substituent is C1-C4 alkoxy and halogenated C1-C4 alkoxy.
10. The compound or pharmaceutically acceptable salt of any one of claims 1, 2, 3, or 6:
R2selected from H, methyl, methoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2,2, 2-trifluoroethoxy.
11. The compound or pharmaceutically acceptable salt of claim 4:
R2selected from H, methyl, methoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2,2, 2-trifluoroethoxy.
12. The compound or pharmaceutically acceptable salt of claim 5:
R2selected from H, methyl, methoxy, 2-methoxyethoxy, 3-methoxypropoxy, 2,2, 2-trifluoroethoxy.
13. The compound or pharmaceutically acceptable salt of any one of claims 1, 2, 3,6, 8, 9, 11, or 12:
R3selected from H, C1-C4 alkyl, C1-C4 alkoxy.
14. The compound or pharmaceutically acceptable salt of claim 4:
R3selected from H, C1-C4 alkyl, C1-C4 alkoxy.
15. The compound or pharmaceutically acceptable salt of claim 5:
R3selected from H, C1-C4 alkyl, C1-C4 alkoxy.
16. The compound or pharmaceutically acceptable salt of claim 7:
R3selected from H, C1-C4 alkyl, C1-C4 alkoxy.
17. The compound or pharmaceutically acceptable salt of claim 10:
R3selected from H, C1-C4 alkyl, C1-C4 alkoxy.
18. The compound or pharmaceutically acceptable salt of any one of claims 1, 2, 3,6, 8, 9, 11, or 12:
R3selected from H, methyl and methoxy.
19. The compound or pharmaceutically acceptable salt of claim 4:
R3selected from H, methyl and methoxy.
20. The compound or pharmaceutically acceptable salt of claim 5:
R3selected from H, methyl and methoxy.
21. The compound or pharmaceutically acceptable salt of claim 7:
R3selected from H, methyl and methoxy.
22. The compound or pharmaceutically acceptable salt of claim 10:
R3selected from H, methyl and methoxy.
23. A compound or pharmaceutically acceptable salt of:
bis (. mu. -sulfate-O, O ') bis {2- [ (3, 4-dimethoxy-2-pyridyl) methylthio ] -1H-benzimidazol-N, N ' ' -ylidene } cupro-nium;
bis (. mu. -sulfate-O, O ') bis {2- [ (3, 4-dimethoxy-2-pyridyl) methylthio ] -1H-benzimidazol-N, N ' ' -ylidene } cupro-methanol solvate;
bis (. mu. -sulfate-O, O ') bis { 5-difluoromethoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio ] -1H-benzimidazol-N, N' -ylidene } cupra;
bis (μ -sulfate-O, O') bis {2- { [ 3-methyl-4- (2,2, 2-trifluoromethoxy) -2-pyridyl ] methylthio } -1H-benzoimidazol-N, N "-ylidene } cupro-nium;
bis (. mu. -sulfate-O, O ') bis { 5-methoxy-2- [ (4-methoxy-3, 5-dimethyl-2-pyridyl) methylthio ] -1H-benzimidazol-N, N' -ylidene } cupro-bium;
bis (. mu. -sulfate-O, O ') bis {2- [ (4-methoxy-3, 5-dimethyl-2-pyridyl) methylthio ] -1H-benzimidazol-N, N' -ylidene } cupro-nium;
bis (μ -sulfate-O, O') bis { 5-difluoromethoxy-2- [ (4-methoxy-3, 5-dimethyl-2-pyridyl) methylthio ] -1H-benzimidazol-N, N "-ylidene } cupro-di;
bis (. mu. -sulfate-O, O ') bis { 5-methoxy-2- { [4- (2-methoxypropoxy) -3, 5-dimethyl-2-pyridinyl ] methylthio } -1H-benzimidazol-N, N' -ylidene } cupro-nium;
bis (μ -sulfate-O, O') bis { 5-methoxy-2- { [ 2-methyl-4- (2,2, 2-trifluoromethyl) -2-pyridinyl ] methylthio } -1H-benzimidazol-N, N "-ylidene } cupro-nium;
bis (. mu. -sulfate-O, O ') bis { 5-methoxy-2- [ (3, 4-dimethoxy-2-pyridyl) methylthio ] -1H-benzimidazol-N, N' -ylidene } cupro-biscopper.
24. A process for preparing a compound or pharmaceutically acceptable salt according to claim 1,
Figure 466085DEST_PATH_IMAGE002
。
25. a pharmaceutical composition comprising as active ingredient a compound or pharmaceutically acceptable salt according to any one of claims 1-23 and a pharmaceutically acceptable carrier or excipient.
26. Use of a compound or pharmaceutically acceptable salt according to any one of claims 1 to 23 or a pharmaceutical composition according to claim 25 for the manufacture of a medicament for the treatment of a tumour.
27. Use according to claim 26, characterized in that: the tumor is liver cancer, colon cancer or rectal cancer.
CN201810184361.4A 2018-03-07 2018-03-07 Complex of copper and benzimidazole compound containing pyridine and application thereof Active CN108299473B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810184361.4A CN108299473B (en) 2018-03-07 2018-03-07 Complex of copper and benzimidazole compound containing pyridine and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810184361.4A CN108299473B (en) 2018-03-07 2018-03-07 Complex of copper and benzimidazole compound containing pyridine and application thereof

Publications (2)

Publication Number Publication Date
CN108299473A CN108299473A (en) 2018-07-20
CN108299473B true CN108299473B (en) 2020-04-17

Family

ID=62849255

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810184361.4A Active CN108299473B (en) 2018-03-07 2018-03-07 Complex of copper and benzimidazole compound containing pyridine and application thereof

Country Status (1)

Country Link
CN (1) CN108299473B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999528A (en) * 2006-12-29 2007-07-18 中国科学院长春应用化学研究所 Copper (1) compound with imidazole derivate as compounding body
CN103130841A (en) * 2013-03-25 2013-06-05 南京工业大学 5- (naphthyridine-4-yl) triazole derivative transition metal complex and luminescence application
CN103540157A (en) * 2013-10-31 2014-01-29 湘潭大学 Polymeric metal-complex functional dye containing 2-(2'-pyridyl)benzimidazole D-pi-A type structure and preparation method thereof
CN103923126A (en) * 2014-03-26 2014-07-16 合肥学院 Dikaryotic cobalt complex and preparation method thereof
CN105481944A (en) * 2015-12-10 2016-04-13 华南农业大学 Benzimidazole derivative dipeptide copper complex, and preparation method and applications thereof
CN106117178A (en) * 2016-06-16 2016-11-16 合肥工业大学 A kind of cobalt complex

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120142658A1 (en) * 2009-06-08 2012-06-07 Centre National De La Recherche Scientifique Therapeutical use of ternary complexes of valproic acid

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100999528A (en) * 2006-12-29 2007-07-18 中国科学院长春应用化学研究所 Copper (1) compound with imidazole derivate as compounding body
CN103130841A (en) * 2013-03-25 2013-06-05 南京工业大学 5- (naphthyridine-4-yl) triazole derivative transition metal complex and luminescence application
CN103540157A (en) * 2013-10-31 2014-01-29 湘潭大学 Polymeric metal-complex functional dye containing 2-(2'-pyridyl)benzimidazole D-pi-A type structure and preparation method thereof
CN103923126A (en) * 2014-03-26 2014-07-16 合肥学院 Dikaryotic cobalt complex and preparation method thereof
CN105481944A (en) * 2015-12-10 2016-04-13 华南农业大学 Benzimidazole derivative dipeptide copper complex, and preparation method and applications thereof
CN106117178A (en) * 2016-06-16 2016-11-16 合肥工业大学 A kind of cobalt complex

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Determination of the absolute configuration and identity of chiral carboxylic acids using a Cu(II) complex of pyridine–benzimidazole based ligand;Shuang Zhao et al.;《Tetrahedron Letters》;20140220;第55卷;第2097-2100页 *
Trigonal Planar Copper(I) Complex: Synthesis, Structure, and Spectra of a Redox Pair of Novel Copper(II/I) Complexes of Tridentate Bis(benzimidazol-2′-yl) Ligand Framework as Models for Electron-Transfer Copper Proteins;Mallayan Palaniandavar et al.;《Inorg. Chem.》;20000403;第40卷;第2246-2255页 *

Also Published As

Publication number Publication date
CN108299473A (en) 2018-07-20

Similar Documents

Publication Publication Date Title
WO2017162108A1 (en) Pillararene complex, preparation method, pharmaceutical composition and use thereof
CA2804034C (en) Prodrugs of heteraromatic compounds
US10323044B2 (en) Crystal of imidazo-oxazine, pharmaceutical composition containing said crystal, and method for producing said crystal
CN113336768B (en) Multi-target tyrosine kinase inhibitor
CN116917288A (en) 7, 9-dihydro purine derivative and pharmaceutical application thereof
WO1995028939A1 (en) Medicinal composition as a remedy for nonsmall cell lung cancer
CN108822126B (en) Thienopyran formyl piperazine compound and medical application thereof
WO2021143954A2 (en) Crystalline form of fluvatinib or fluvatinib methanesulfonate and preparation method therefor
CN108299473B (en) Complex of copper and benzimidazole compound containing pyridine and application thereof
CN108148097B (en) Pyridine-containing cobalt complex of benzimidazole compound and application thereof
CN108218925B (en) Cobalt complex of imidazopyridine compound and application thereof
CN108358953B (en) Copper and imidazopyridine compound complex and application thereof
EP3368543B1 (en) Oxysterols and hedgehog signaling
WO2020216188A1 (en) Crystal forms of compound, preparation method therefor, pharmaceutical composition and application thereof
WO2019001307A1 (en) Amide compound, composition containing same, and use thereof
EP2902028A1 (en) Drug composition for treating tumors and application thereof
JP2002527518A (en) New pterin antineoplastics
CN113710660B (en) DOT1L degradation agent and application thereof
CN108586485B (en) 1- (4-hydroxyiminothieno [2,3-b ] thiopyranoformyl) piperazine compound and application thereof
CN110698491B (en) 2- (camptothecin-10-oxyl) acetamide compound and application thereof
CN108484635B (en) 4H-thieno [2,3-b ] thiopyran-4-one compound and application thereof
WO2012136144A1 (en) Camptothecin derivatives having anti-tumor activity
CN109422731A (en) Deuterated quinoline
CN103304556B (en) Schiff bases compounds containing chromene, Preparation Method And The Use
CN114957137B (en) N- (1, 2,3, 6-tetrahydropyrimidine-4-yl) -2-phenylacetamide compound and preparation and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant